|
Roche was one of the first companies to bring targeted treatments to patients. With our combined strength in pharmaceuticals and diagnostics, we are better equipped than any other company to further drive personalised healthcare. Two-thirds of our Research and Development projects are being developed with companion diagnostics. |
|
|
Our scientific heritage is grounded in pushing the boundaries of small molecule discovery and development. For decades, our scientists have led the way in identifying the right chemical leads. Our early discovery and high throughput screening capabilities enable us to screen thousands of compounds a day to identify molecules with potential to inhibit or activate the target. |
|
|
As one of the world’s largest and most active venture capital firms, NEA has developed deep domain expertise and insight into our industries of focus. We channel that knowledge into every technology and healthcare investment we make — at any stage, in any location, around the globe. |
|
|
Alexandria Real Estate Equities, Inc. (NYSE: ARE), an S&P 500® company, is a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world. As the pioneer of the life science real estate niche since its founding in 1994, Alexandria is the preeminent and longest-tenured owner, operator, and developer of collaborative life science, agtech, and technology campuses in AAA innovation cluster locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. In Maryland, Alexandria has established a significant presence of approximately 4 million square feet of high-quality office/laboratory space primarily located in Rockville and Gaithersburg. As one of Maryland’s most active early-stage investors, Alexandria also actively invests in disruptive life science companies as well as promising agrifoodtech, climate innovation, and technology companies through its strategic venture capital platform, Alexandria Venture Investments. |
|
|
Noble Life Sciences is a preclinical contract research organization (CRO) owned and operated by scientists with decades of experience in drug, vaccine, and medical device development. In addition to offering GLP and non-GLP services including in-vivo and in-vitro specialized models, Noble’s team of scientists implement effective and efficient approaches to help guide your research and development programs. |
|
In the 8-0 vote, the Council approved the Plan dubbed “LifeSci Village,” a joint venture of the county and private developer Percontee. It encompasses 300 acres off Route 29 and Industrial Parkway in the White Oak area of Silver Spring, adjacent to the Food and Drug Administration headquarters. The development will include housing and retail and will become the newsest hub for medical and life-sciences research in the county.
Image: http://www.choosemontgomerymd.com
What do you need to turn a brilliant idea into a business? “A good morale boost,” says Abhishek Motayed, Founder and President of N5 Sensors, Inc. of Rockville. Motayed had that boost this month when N5 Sensors received two Small Business Innovation Research (SBIR) awards totaling $250,000. The grants came from the Environmental Protection Agency (EPA) and the National Science Foundation (NSF) towards N5 Sensors work developing low-power, computer chip-size benzene, carbon monoxide, and ammonia sensors. A 2012 UMD Invention of Year Award winner, Motayed has kept close contact with the university’s Office of Technology Commercialization (OTC), a crucial participant in the creation of N5 Sensors. “My interactions with OTC were very positive and encouraging. They are very knowledgeable—they knew exactly how to advise me on funding, commercialization, and patenting,” says Motayed.
Apollo Hospitals announced the launch of cutting-edge clinical genomic tests from the Strand Center for Genomics and Personalized Medicine, a part of Strand Life Sciences across its hospital network. These tests in oncology, cardiovascular, heritable eye diseases and rare genetic disorders shall be integrated into clinical practice by Apollo’s subsidiary, Sapien Biosciences in partnership with Strand Life Sciences. These tests, will help doctors diagnose disease more precisely, identify the optimal treatment and monitor disease & treatment course for better outcomes. Genomics is integral to Apollo’s focus on Research and Innovations. Genomic testing involves analyses of patient genomes – genes and sequences of DNA/RNA. The analysis helps create better prognostic tools for improved disease screening and prevention strategies. The patient benefits from optimized clinical care, personalization of treatment & monitoring of outcomes. These tests come with comprehensive pre- & post-test counselling to help the patient & their physicians to integrate the tests results into the clinical care provided. Ms. Sangita Reddy, Joint Managing Director, Apollo Hospitals says,“Apollo has always believed that personalized medicine is the future of healthcare delivery. Our Chairman, Dr. P.C Reddy’s foresight of personalized health is becoming a reality today with the availability of such cutting-edge genomic tests.”
